Creative Biolabs Advances in the Discovery of SARS-CoV-2 Inhibitors
New York, USA – December 26, 2023 – Through its all-encompassing anti-SARS-CoV-2 candidate discovery and development platform, Creative Biolabs offers a suite of antiviral drug discovery services designed to aid researchers in identifying potent antiviral products capable of effectively impeding virus replication in vitro, ex vivo, and in vivo.
Nucleoside Analogue Inhibitors
Among the arsenal of services provided by Creative Biolabs is the exploration of nucleoside analogue inhibitors. Notably, Remdesivir, an FDA-approved nucleoside analogue drug for treating COVID-19, stands out. The adept research team at Creative Biolabs offers a diverse range of nucleoside analog discovery services. In addition to Remdesivir, it also extends its development services to Acyclovir for SARS-CoV-2.
“Our experts emphasize that Acyclovir, originally formulated to combat herpes virus infections, has found a new purpose as an inhibitor of viral DNA polymerase. It represents a cost-effective, safe, and well-tolerated alternative for treating mild to severe COVID-19 cases,” explained Creative Biolabs’ antiviral drug research experts.
Furthermore, Creative Biolabs’ portfolio of nucleoside analogue inhibitors includes Ribavirin, Beta-D-N4-Hydroxycytidine, Mizoribine, Gemcitabine Hydrochloride, and more.
Viral Protease Inhibitors
In the quest to combat SARS-CoV-2 infections, protease inhibitors have emerged as a noteworthy class of drugs, given the involvement of multiple proteases in the lifecycle of SARS-CoV-2.
Creative Biolabs provides discovery services for a variety of protease inhibitors, such as Crixivan, originally designed for HIV; and Saquinavir, initially developed as an HIV protease inhibitor but has demonstrated stable binding affinity with coronavirus protease and can be considered a clinical candidate.
“To aid researchers in the study of protease inhibitors, Creative Biolabs offers protease assays, facilitating the acceleration of anti-SARS-CoV-2 therapy development,” added the expert.
Abelson Kinase Inhibitors
Creative Biolabs’ SARS-CoV-2 research team delves into the development of small-molecule inhibitors, particularly small-molecule kinase inhibitors. These inhibitors show promise in effectively combating coronavirus infections in vitro.
Creative Biolabs offers the development of Abelson kinase inhibitors for SARS-CoV-2. “Research indicates that Abl inhibitors can hinder SARS-CoV and MERS-CoV, underscoring the significance of the Abl pathway in coronavirus replication. Consequently, Abl pathway inhibitors hold immense potential as broad-spectrum antiviral drugs.”
Beyond diverse SARS-CoV-2 inhibitors, Creative Biolabs tailors solutions for researchers globally, employing techniques such as high-throughput screening, neutralizing antibody development, antiviral peptide discovery, and more.
For additional information on the services offered by Creative Biolabs’ comprehensive anti-SARS-CoV-2 platform, please visit https://sars-cov-2.creative-biolabs.com.
About
Creative Biolabs, a biotechnology company with extensive experience in the discovery and development of SARS-CoV-2 drugs, not only provides top-tier services but also actively collaborates with the global scientific community to collectively seek effective antiviral solutions in the ongoing global emergency situation of combating COVID-19.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://sars-cov-2.creative-biolabs.com
